Company Filing History:
3 out of 4,948 
2 out of 46 
Years Active: 2015-2024
Title: Sabine Sewing: Innovator in Oligonucleotide Technology
Introduction
Sabine Sewing is a prominent inventor based in Basel, Switzerland. She has made significant contributions to the field of oligonucleotide technology, holding a total of 5 patents. Her work focuses on innovative methods for treating viral infections and predicting drug toxicity.
Latest Patents
One of her latest patents is titled "Enhanced oligonucleotides for inhibiting RTEL1 expression." This invention provides antisense oligonucleotides that target the Regulator of Telomere Elongation Helicase 1 (RTEL1). The disclosure also includes enhanced antisense oligonucleotides aimed at treating and preventing hepatitis B virus (HBV) infections. Additionally, she has developed an "In vitro nephrotoxicity screening assay," which relates to methods for predicting the in vivo nephrotoxicity of drug substances, particularly nucleic acid molecules like siRNA or antisense oligonucleotides. This assay measures the levels of extracellular EGF as a toxicity biomarker, potentially in combination with other biomarkers such as ATP and KIM-1.
Career Highlights
Throughout her career, Sabine has worked with notable companies, including Hoffmann-La Roche Inc. and Roche Innovation Center Copenhagen A/S. Her expertise in oligonucleotide technology has positioned her as a key player in the pharmaceutical industry.
Collaborations
Some of her notable coworkers include Annie Moisan and Marcel Gubler, who have collaborated with her on various projects.
Conclusion
Sabine Sewing's innovative work in oligonucleotide technology has led to significant advancements in the treatment of viral infections and drug toxicity prediction. Her contributions continue to impact the field and inspire future research.